(Adnkronos) - "Circa un quarto dei nostri addetti alla ricerca e sviluppo si trova in Europa, in particolare in Italia. Un Paese che contribuisce significativamente anche agli studi clinici che portiamo avanti”. Così Pablo Cagnoni, M.D., President and Head of Research & Development Incyte, intervenuto al Forum Incyte sulla Ricerca, con focus su capitale umano ed economico, le leve strategiche per valorizzare la ricerca in Italia, svoltosi a Roma e promosso dall’azienda biofarmaceutica Incyte Italia, in collaborazione con Formiche e Healthcare Policy.
Category
🗞
NewsTranscript
00:00In Insight, we are committed to research and development of innovative solutions that can improve the lives of patients,
00:11with a focus on therapeutic areas and high unmet need, in which patients have limited therapeutic options or even none.
00:21To carry out this global challenge, we invest more than 40% of our revenue in research and development, which amounts to more than 1.5 billion dollars per year.
00:32In this scenario, Europe and Italy play a key role. About a quarter of our research and development dependents are in Europe,
00:40especially in Italy, a country that significantly contributes to the clinical studies we carry out.
00:47Only in 2024, we have enrolled more than 120 patients in clinical trials in Italy.
00:54The main challenges for the future remain those of today, continuing to finance the extraordinary wave of innovation
01:01that is crossing the biopharmaceutical industry and developing new approaches and collaborations to improve the lives of patients.